{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:52:30Z","timestamp":1781614350989,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study examined the longitudinal changes in metabolic liver function and MR-morphological dilatation of intrahepatic bile ducts in patients with stereotactic body radiation therapy (SBRT) for liver metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 64 patients with SBRT of 84 liver metastases between February 2005 and January 2019. To evaluate hepatobiliary toxicity, the laboratory parameters albumin, alanine-transaminase (ALAT), aspartate-transaminase (ASAT), bilirubin and gamma-glutamyltransferase (GGT) and the qualitative dilatation of MR-morphological peritumoural, intrahepatic bile ducts were analyzed from pre- up to 12 months post-SBRT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The liver metastases were irradiated with a median D50 to the GTV of BED\n                      <jats:sub>\u03b1\/\u03b2=10\u00a0Gy<\/jats:sub>\n                      = 134\u00a0Gy (range 51\u2013219\u00a0Gy) resulting in a median mean dose D\n                      <jats:sub>mean<\/jats:sub>\n                      -L-EQD2\n                      <jats:sub>\u03b1\/\u03b2=3\u00a0Gy<\/jats:sub>\n                      = 11.8\u00a0Gy (range 0.4\u201365.6\u00a0Gy) to the total liver. The central hepatobiliary tract (cHBT) was exposed to a median D\n                      <jats:sub>mean<\/jats:sub>\n                      -cHBT-BED\n                      <jats:sub>\u03b1\/\u03b2=10\u00a0Gy<\/jats:sub>\n                      = 8.3\u00a0Gy (range 0.1\u201381.6\u00a0Gy). Significant decreases in albumin and increases in GGT and bilirubin were observed up to 12 months post-SBRT. D\n                      <jats:sub>mean<\/jats:sub>\n                      -L-EQD2\n                      <jats:sub>\u03b1\/\u03b2=3\u00a0Gy<\/jats:sub>\n                      , D\n                      <jats:sub>mean<\/jats:sub>\n                      -cHBT-BED\n                      <jats:sub>\u03b1\/\u03b2=10\u00a0Gy<\/jats:sub>\n                      and VBED\n                      <jats:sub>\u03b1\/\u03b2=10Gy<\/jats:sub>\n                      66Gy-cHBT and VBED\n                      <jats:sub>\u03b1\/\u03b2=10Gy<\/jats:sub>\n                      72Gy-cHBT were significant cofactors influencing the course of GGT, ASAT and bilirubin, but not for albumin and ALAT. MR-morphological, short- and long-term dilatation of peritumoural bile ducts were associated with significant higher VBED\n                      <jats:sub>\u03b1\/\u03b2=10Gy<\/jats:sub>\n                      66Gy-cHBT and VBED\n                      <jats:sub>\u03b1\/\u03b2=10Gy<\/jats:sub>\n                      72Gy-cHBT values and were significantly more frequent for SBRT of target volumes with &lt;\u20093\u00a0cm distance to the cHBT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>SBRT of liver metastases was associated with minor alterations in metabolic liver function. High dose exposure and proximity of the liver metastases to the cHBT may lead to locoregional bile duct dilatation after SBRT. Further evaluation of metabolic and MR-morphological changes in liver function is recommended in personalised oncological treatment approaches for liver-directed therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-025-02731-7","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T07:23:39Z","timestamp":1760340219000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of metabolic liver function and MR-morphological cholestatic parameters after SBRT of liver metastases"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5671-9389","authenticated-orcid":false,"given":"Constantin","family":"Dreher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Wojtal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren","family":"Johann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia S.","family":"Bicu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Kaestner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Hetjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoshirwan A.","family":"Tavakoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"N\u00f6renberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Blanck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Oppitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Buergy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank A.","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Boda-Heggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"issue":"20","key":"2731_CR1","doi-asserted-by":"publisher","first-page":"6113","DOI":"10.3748\/wjg.v20.i20.6113","volume":"20","author":"\u00d6 Akg\u00fcl","year":"2014","unstructured":"Akg\u00fcl \u00d6, \u00c7etinkaya E, Ers\u00f6z \u015e, Tez M. Role of surgery in colorectal cancer liver metastases. World J Gastroenterology: WJG. 2014;20(20):6113.","journal-title":"World J Gastroenterology: WJG"},{"issue":"24","key":"2731_CR2","doi-asserted-by":"publisher","first-page":"5971","DOI":"10.1158\/1078-0432.CCR-16-0460","volume":"22","author":"P Brodt","year":"2016","unstructured":"Brodt P. Role of the microenvironment in liver metastasis: from pre-to prometastatic niches. Clin Cancer Res. 2016;22(24):5971\u201382.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2731_CR3","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1038\/modpathol.3800682","volume":"20","author":"ZD Goodman","year":"2007","unstructured":"Goodman ZD. Neoplasms of the liver. Mod Pathol. 2007;20(1):S49\u201360.","journal-title":"Mod Pathol"},{"issue":"15","key":"2731_CR4","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1177\/1535370216658144","volume":"241","author":"AM Clark","year":"2016","unstructured":"Clark AM, Ma B, Taylor DL, Griffith L, Wells A. Liver metastases: microenvironments and ex-vivo models. Experimental Biology Med. 2016;241(15):1639\u201352.","journal-title":"Experimental Biology Med"},{"issue":"1","key":"2731_CR5","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1186\/1471-2407-14-810","volume":"14","author":"C Hackl","year":"2014","unstructured":"Hackl C, Neumann P, Gerken M, Loss M, Klinkhammer-Schalke M, Schlitt HJ. Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer. 2014;14(1):810.","journal-title":"BMC Cancer"},{"issue":"19","key":"2731_CR6","first-page":"335","volume":"107","author":"UP Neumann","year":"2010","unstructured":"Neumann UP, Seehofer D, Neuhaus P. The surgical treatment of hepatic metastases in colorectal carcinoma. Dtsch Arztebl Int. 2010;107(19):335\u201342.","journal-title":"Dtsch Arztebl Int"},{"key":"2731_CR7","doi-asserted-by":"crossref","unstructured":"Dawson LA, editor. Editor overview: where does radiation therapy fit in the spectrum of liver cancer local-regional therapies? Seminars in radiation oncology. Elsevier; 2011.","DOI":"10.1016\/j.semradonc.2011.05.009"},{"issue":"1","key":"2731_CR8","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, Nandita Md, et al. Characterisation and classification of oligometastatic disease: a European society for radiotherapy and oncology and European organisation for research and treatment of cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18\u201328.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2731_CR9","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.radonc.2016.10.024","volume":"122","author":"DA Toesca","year":"2017","unstructured":"Toesca DA, Osmundson EC, von Eyben R, Shaffer JL, Lu P, Koong AC, et al. Central liver toxicity after SBRT: an expanded analysis and predictive nomogram. Radiother Oncol. 2017;122(1):130\u20136.","journal-title":"Radiother Oncol"},{"issue":"10","key":"2731_CR10","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1200\/JCO.2008.20.0600","volume":"27","author":"MT Lee","year":"2009","unstructured":"Lee MT, Kim JJ, Dinniwell R, Brierley J, Lockwood G, Wong R, et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009;27(10):1585\u201391.","journal-title":"J Clin Oncol"},{"issue":"3 Suppl","key":"2731_CR11","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1016\/j.ijrobp.2009.06.092","volume":"76","author":"CC Pan","year":"2010","unstructured":"Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S94\u2013100.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2731_CR12","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.semradonc.2011.05.003","volume":"21","author":"C Guha","year":"2011","unstructured":"Guha C, Kavanagh BD. Hepatic radiation toxicity: avoidance and amelioration. Semin Radiat Oncol. 2011;21(4):256\u201363.","journal-title":"Semin Radiat Oncol"},{"issue":"10","key":"2731_CR13","first-page":"872","volume":"190","author":"F Sterzing","year":"2014","unstructured":"Sterzing F, Brunner TB, Ernst I, Baus WW, Greve B, Herfarth K, et al. Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO working group on stereotactic Radiotherapy. Strahlentherapie und onkologie. Organ Der Deutschen Rontgengesellschaft [et al]. 2014;190(10):872\u201381.","journal-title":"Organ Der Deutschen Rontgengesellschaft [et al]"},{"issue":"4","key":"2731_CR14","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.ijrobp.2011.09.045","volume":"83","author":"M Velec","year":"2012","unstructured":"Velec M, Moseley JL, Craig T, Dawson LA, Brock KK. Accumulated dose in liver stereotactic body radiotherapy: positioning, breathing, and deformation effects. Int J Radiat Oncol Biol Phys. 2012;83(4):1132\u201340.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"suppl1","key":"2731_CR15","doi-asserted-by":"publisher","first-page":"i40","DOI":"10.1093\/jrr\/rrx104","volume":"59","author":"DAS Toesca","year":"2018","unstructured":"Toesca DAS, Ibragimov B, Koong AJ, Xing L, Koong AC, Chang DT. Strategies for prediction and mitigation of radiation-induced liver toxicity. J Radiat Res. 2018;59(suppl1):i40\u20139.","journal-title":"J Radiat Res"},{"issue":"1","key":"2731_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ijrobp.2021.09.027","volume":"112","author":"R Timmerman","year":"2022","unstructured":"Timmerman R. A story of hypofractionation and the table on the wall. Int J Radiat Oncol Biol Phys. 2022;112(1):4\u201321.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"2731_CR17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.semradonc.2018.06.007","volume":"28","author":"EJ Koay","year":"2018","unstructured":"Koay EJ, Owen D, Das P. Radiation-Induced liver disease and modern radiotherapy. Semin Radiat Oncol. 2018;28(4):321\u201331.","journal-title":"Semin Radiat Oncol"},{"issue":"5","key":"2731_CR18","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ijrobp.2014.11.028","volume":"91","author":"EC Osmundson","year":"2015","unstructured":"Osmundson EC, Wu Y, Luxton G, Bazan JG, Koong AC, Chang DT. Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract. Int J Radiat Oncol Biol Phys. 2015;91(5):986\u201394.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2731_CR19","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.radonc.2016.10.024","volume":"122","author":"DA Toesca","year":"2017","unstructured":"Toesca DA, Osmundson EC, Eyben RV, Shaffer JL, Lu P, Koong AC, et al. Central liver toxicity after SBRT: an expanded analysis and predictive nomogram. Radiother Oncol. 2017;122(1):130\u20136.","journal-title":"Radiother Oncol"},{"key":"2731_CR20","first-page":"46","volume":"65","author":"J Boda-Heggemann","year":"2019","unstructured":"Boda-Heggemann J, Sihono DSK, Streb L, Mertens L, Vogel L, Stieler F, et al. Ultrasound-based repositioning and real-time monitoring for abdominal SBRT in DIBH. Physica medica: PM: an international journal devoted to the applications of physics to medicine and biology. Official J Italian Association Biomedical Phys. 2019;65:46\u201352.","journal-title":"Official J Italian Association Biomedical Phys"},{"key":"2731_CR21","unstructured":"Daamen LA, Heerkens HD, Molenaar IQQ, Verkooijen HLM, Meijer GJ, Intven MPW. [MRI-guided radiotherapy: an innovation for patients with upper abdominal malignancies]. Ned Tijdschr Geneeskd. 2020;164."},{"issue":"7","key":"2731_CR22","doi-asserted-by":"publisher","first-page":"886","DOI":"10.3109\/0284186X.2015.1137352","volume":"55","author":"C Dreher","year":"2016","unstructured":"Dreher C, Hoyer KI, Fode MM, Habermehl D, Combs SE, Hoyer M. Metabolic liver function after stereotactic body radiation therapy for hepatocellular carcinoma. Acta Oncol (Stockholm Sweden). 2016;55(7):886\u201391.","journal-title":"Acta Oncol (Stockholm Sweden)"},{"issue":"3","key":"2731_CR23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/0284186X.2023.2187707","volume":"62","author":"C Dreher","year":"2023","unstructured":"Dreher C, Sarria GR, Miebach G, Weiss C, Buergy D, Wojtal P, et al. Long-term characterization of MRI-morphologic alterations after active motion-compensated liver SBRT: a multi-institutional pooled analysis. Acta Oncol (Stockholm Sweden). 2023;62(3):281\u20139.","journal-title":"Acta Oncol (Stockholm Sweden)"},{"issue":"9","key":"2731_CR24","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00066-016-1013-9","volume":"192","author":"J Boda-Heggemann","year":"2016","unstructured":"Boda-Heggemann J, Attenberger U, Budjan J, Jahnke A, Jahnke L, Vogel L, et al. MRI morphologic alterations after liver SBRT: direct dose correlation with intermodal matching. Strahlentherapie Und Onkologie: Organ Der Deutschen Rontgengesellschaft [et al]. 2016;192(9):641\u20138.","journal-title":"Strahlentherapie Und Onkologie: Organ Der Deutschen Rontgengesellschaft [et al]"},{"issue":"5","key":"2731_CR25","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s00066-018-1271-9","volume":"194","author":"J Boda-Heggemann","year":"2018","unstructured":"Boda-Heggemann J, Jahnke A, Chan MKH, Ghaderi Ardekani LS, Hunold P, Schafer JP, et al. Direct dose correlation of MRI morphologic alterations of healthy liver tissue after robotic liver SBRT. Strahlentherapie Und Onkologie: Organ Der Deutschen Rontgengesellschaft [et al]. 2018;194(5):414\u201324.","journal-title":"Strahlentherapie Und Onkologie: Organ Der Deutschen Rontgengesellschaft [et al]"},{"issue":"3","key":"2731_CR26","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.ijrobp.2015.11.049","volume":"94","author":"J Boda-Heggemann","year":"2016","unstructured":"Boda-Heggemann J, Knopf AC, Simeonova-Chergou A, Wertz H, Stieler F, Jahnke A, et al. Deep inspiration breath hold-based radiation therapy: A clinical review. Int J Radiat Oncol Biol Phys. 2016;94(3):478\u201392.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2731_CR27","doi-asserted-by":"crossref","unstructured":"Krug D, Blanck O, Boda-Heggemann J, Dunst J. Stereotaktische strahlentherapie f\u00fcr Lebermetastasen. Zentralblatt f\u00fcr Chirurgie-Zeitschrift f\u00fcr Allgemeine, Viszeral-, Thorax-und Gef\u00e4\u00dfchirurgie. 2019;144(03):242\u201351.","DOI":"10.1055\/a-0883-6583"},{"issue":"7","key":"2731_CR28","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1080\/02841860600904870","volume":"45","author":"BD Kavanagh","year":"2006","unstructured":"Kavanagh BD, Schefter TE, Cardenes HR, Stieber VW, Raben D, Timmerman RD, et al. Interim analysis of a prospective phase I\/II trial of SBRT for liver metastases. Acta Oncol. 2006;45(7):848\u201355.","journal-title":"Acta Oncol"},{"issue":"10","key":"2731_CR29","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1200\/JCO.2008.19.6329","volume":"27","author":"KE Rusthoven","year":"2009","unstructured":"Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, et al. Multi-institutional phase I\/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27(10):1572\u20138.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2731_CR30","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.ijrobp.2009.09.009","volume":"78","author":"SH Son","year":"2010","unstructured":"Son SH, Choi BO, Ryu MR, Kang YN, Jang JS, Bae SH, et al. Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication. Int J Radiat Oncol Biol Phys. 2010;78(4):1073\u201380.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2731_CR31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.semradonc.2017.02.001","volume":"27","author":"EL Pollom","year":"2017","unstructured":"Pollom EL, Chin AL, Diehn M, Loo BW, Chang DT. Normal tissue constraints for abdominal and thoracic stereotactic body radiotherapy. Semin Radiat Oncol. 2017;27(3):197\u2013208.","journal-title":"Semin Radiat Oncol"},{"issue":"3","key":"2731_CR32","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s00066-018-1385-0","volume":"195","author":"E Gkika","year":"2019","unstructured":"Gkika E, Strouthos I, Kirste S, Adebahr S, Schultheiss M, Bettinger D, et al. Repeated SBRT for in- and out-of-field recurrences in the liver. Strahlenther Onkol. 2019;195(3):246\u201353.","journal-title":"Strahlenther Onkol"},{"issue":"5","key":"2731_CR33","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1016\/j.prro.2017.03.004","volume":"7","author":"A Barry","year":"2017","unstructured":"Barry A, McPartlin A, Lindsay P, Wang L, Brierley J, Kim J, et al. Dosimetric analysis of liver toxicity after liver metastasis stereotactic body radiation therapy. Pract Radiat Oncol. 2017;7(5):e331\u20137.","journal-title":"Pract Radiat Oncol"},{"issue":"3","key":"2731_CR34","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.radonc.2018.01.004","volume":"126","author":"DH Moon","year":"2018","unstructured":"Moon DH, Wang AZ, Tepper JE. A prospective study of the safety and efficacy of liver stereotactic body radiotherapy in patients with and without prior liver-directed therapy. Radiother Oncol. 2018;126(3):527\u201333.","journal-title":"Radiother Oncol"},{"key":"2731_CR35","doi-asserted-by":"crossref","unstructured":"Brunner TB, Boda-Heggemann J, B\u00fcrgy D, Corradini S, Dieckmann UK, Gawish A et al. Dose prescription for stereotactic body radiotherapy: general and organ-specific consensus statement from the DEGRO\/DGMP working group stereotactic radiotherapy and Radiosurgery. Strahlentherapie und onkologie: organ der Deutschen Rontgengesellschaft. 2024;200(9):737\u201350.","DOI":"10.1007\/s00066-024-02254-2"},{"key":"2731_CR36","doi-asserted-by":"crossref","unstructured":"Hong TS, Wo JY, Borger DR, Yeap BY, McDonnell EI, Willers H et al. Phase II study of Proton-Based stereotactic body radiation therapy for liver metastases: importance of tumor genotype. J Natl Cancer Inst. 2017;109(9).","DOI":"10.1093\/jnci\/djx031"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02731-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-025-02731-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02731-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:00:49Z","timestamp":1781611249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13014-025-02731-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2731"],"URL":"https:\/\/doi.org\/10.1186\/s13014-025-02731-7","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data were evaluated retrospectively after the approval of the local ethics committee of the medical faculty Mannheim, University of Heidelberg, Germany (2018-869R-MA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C.D. reports Varian research grant and travel expenses, AstraZeneca speaker fees and travel expenses, and DGVS speaker fees and travel expenses.D.B. reports personal fees from NB Capital ApS, personal fees from Nordic Biotech, speaker fees from AstraZeneca, outside the submitted work. F.A.G. reports travel expenses, stocks and honoraria from TME Pharma AG; research grants and travel expenses from ELEKTA AB; grants, research grants, travel expenses and honoraria from Carl Zeiss Meditec AG; grants, research grants, travel expenses and honoraria from Biotex, Inc.; travel expenses and research grants from Varian Medical Systems, Inc.; travel expenses and\/or honoraria from Bristol-Myers Squibb, Cureteq AG, Roche Pharma AG, MSD Sharp and Dohme GmbH, Siemens Healthineers AG, Varian Medical Systems, and AstraZeneca GmbH; non-financial support from Oncare GmbH and Opasca GmbH and patent US10857388B2 together with Carl Zeiss Meditec AG; all unrelated to this work. L.K. reports AstraZeneca speaker fees.J. B.-H. reports Elekta research grant, EBAMed consulting fees, AstraZeneca speaker fees.All other authors have no competing interests to declare.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"151"}}